Data Characteristics
Gene therapy AAV (adeno-associated virus vector) pharmacovigilance data originates from clinical trial reports, real-world studies, post-market surveillance, and safety data submissions to regulatory bodies. This data typically combines structured and unstructured formats. Structured data includes patient demographics, medication history, Adverse Event (AE) codes (e.g., MedDRA terms), severity, onset date, and outcome, often found in database records. Unstructured data encompasses detailed medical text descriptions, physician notes, patient interview records, laboratory test reports, and imaging reports. Data updates are frequent, especially during the early stages of new drug launches, as regulatory agencies require continuous safety data collection and evaluation. Documents are commonly PDF clinical study reports, drug labels, safety update reports, and XML or JSON formatted database exports. Adverse event severity may use the 1-5 grade Common Terminology Criteria for Adverse Events (CTCAE), while frequency is expressed as "per 1000 patient-years" or as a percentage.
Constraints on Model Integration and Configuration
The highly specialized and multimodal nature of gene therapy AAV pharmacovigilance data imposes specific requirements on model integration and configuration. Its hybrid data structure necessitates processing both structured fields and complex medical unstructured text. Models must effectively parse MedDRA codes and extract key adverse event information, associated drugs, dosages, and onset times from free text. High update frequency demands models capable of incremental learning or rapid retraining to ensure the pharmacovigilance system operates on the latest data. Professional terminology and units, such as CTCAE, within documents require models with strong domain knowledge understanding. This requires incorporating medical dictionaries or ontologies to enhance model semantic comprehension. Furthermore, the unique characteristics of AAV vectors may lead to rare or novel adverse reactions, requiring models to possess generalization capabilities for low-frequency events, avoiding overfitting to common patterns. Models also need to handle format differences from various data sources, such as converting PDF documents to readable text or parsing complex XML structures.
Configuration Guidelines
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
Chunk size (Segment Length) | 800–1200 characters | Balances the completeness of adverse event descriptions in AAV reports with the model's efficiency in processing long texts. |
Overlap Length | 150–200 characters | Ensures continuity of context for adverse event descriptions, preventing critical information from being truncated. |
Similarity threshold (Similarity Threshold) | 0.75 or calibrated with actual data | In highly specialized text, ensures recall results are highly relevant to the query intent. |
Recall count (Recall Count) | Top 8–12 items | Covers the various types of adverse events and related contexts that may be involved in AAV pharmacovigilance. |
LLM_MODEL_NAME | Qwen2-7B-Instruct or higher version | Suitable for processing complex medical text and specialized terminology, providing more accurate semantic understanding. |
MAX_TOKENS_PER_REQUEST | 4096 tokens or adjust based on model limits | Accommodates potentially longer adverse event descriptions and analyses found in AAV pharmacovigilance reports. |
Common Pitfalls
- Models provide irrelevant answers when processing long medical texts. This is due to improper segmentation strategies, leading to critical information being split or context loss.
- The system occasionally returns an
Unexpected end of JSON inputerror. This typically results from network instability between the backend and the large language model API or non-standard JSON formatting from the model. - Adverse event information in uploaded AAV clinical study reports cannot be accurately identified. This may be because the text preprocessing stage did not effectively handle the complex layout of PDF documents, leading to incomplete or disordered text extraction.
Verification Steps
- Upload typical AAV clinical trial reports and safety update documents. Check if the knowledge base content parsing is complete, free of garbled characters, and correctly identifies MedDRA-coded adverse events.
- Conduct multi-round question-answering tests for specific adverse reactions that may occur with AAV drugs (e.g., immunogenicity, off-target effects). Evaluate if the model can accurately recall relevant information and provide reasonable suggestions. The
similaritymetric of the recalled results should exceed the set threshold. - Simulate high-concurrency query scenarios. Monitor system response times and error logs to ensure system stability when handling a large number of AAV pharmacovigilance queries, without timeouts or JSON parsing errors.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.